| Literature DB >> 35770128 |
Keun Hyung Park1, Chan-Young Jung1, Wonjeong Jeong2, Gongmyung Lee1, Jae Seok Yang1, Chung Mo Nam3, Hyung Woo Kim1, Beom Seok Kim1.
Abstract
This study aimed to investigate the impact of nationwide nonpharmaceutical interventions against coronavirus disease 2019 (COVID-19) on the incidence of Pneumocystis jirovecii pneumonia (PCP) in kidney transplant recipients. The monthly incidence of PCP during the COVID-19 period decreased significantly compared to that of the pre-COVID-19 period in kidney transplant recipients.Entities:
Keywords: COVID-19; Pneumocystis jirovecii pneumonia; kidney transplant recipients; nonpharmaceutical interventions
Year: 2022 PMID: 35770128 PMCID: PMC9223043 DOI: 10.1093/ofid/ofac076
Source DB: PubMed Journal: Open Forum Infect Dis ISSN: 2328-8957 Impact factor: 4.423
Figure 1.Trends of monthly Pneumocystis jirovecii pneumonia (PCP) incidence. Regression models were adjusted for age, sex, number of hospitalizations, seasonality, type of immunosuppressive agent, and days after kidney transplantation.
Results of Poisson Regression of the Effects of Nonpharmaceutical Interventions on Pneumocystis jirovecii Pneumonia
| Period | PCP | ||
|---|---|---|---|
| RR | (95% CI) |
| |
| Pre–COVID-19 period | 1.00 | (1.00–1.01) | .103 |
| Intervention | 0.83 | (.77–.91) | <.001 |
| COVID-19 period | 0.93 | (.92–.94) | <.001 |
Regression models were adjusted for age, sex, number of hospitalizations, seasonality, type of immunosuppressive agent, and days after kidney transplantation.
Abbreviations: CI, confidence interval; COVID-19, coronavirus disease 2019; PCP, Pneumocystis jirovecii pneumonia; RR, risk ratio.